Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Combination Strategies A Common Thread In NASH R&D

Executive Summary

Intercept continues to lead the non-alcoholic steatohepatitis race, but some analysts think Gilead is making up ground; data presented at AASLD shows those two, along with Allergan/Tobira and Bristol, are jockeying to produce combination regimens for the unmet medical need.

Advertisement

Related Content

Madrigal Cements Case For Hepatic Fat Reduction, Other NASH Benefits With MGL-3196
Pfizer/Novartis Collaboration Brings Combined Strength To NASH Development
Madrigal May Shake Up NASH Race With Phase II Resolution Data
Pfizer Working To Catch Up In NASH With Fat-Reducing Compounds
Madrigal's Early Phase IIb NASH Data Show Clinically Meaningful Fat Reduction
Gilead Data Suggest Role For ACC Inhibition In NASH
Stealthy NGM And Bristol Emerge As Serious NASH Competitors
Allergan’s Tab For Tobira’s NASH Cocktail With Akarna Chaser Tops $1.7bn
The NASH Pipeline: Replete With Targets And New Compounds
Tobira/Dong-A Partnership Will Add DPP-4 Inhibitor For NASH Combo Therapy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097699

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel